Last updated: February 19, 2026
This analysis examines Japan patent JP2017529380, focusing on its scope, claims, and the broader patent landscape for the disclosed technology. The patent, filed by AbbVie Inc., pertains to pharmaceutical compositions comprising specific protein kinase inhibitors, primarily targeting Janus kinase (JAK) enzymes. The technology is relevant to the treatment of autoimmune and inflammatory diseases.
What is the core innovation protected by JP2017529380?
JP2017529380 protects novel pharmaceutical compositions containing Janus kinase (JAK) inhibitors. The primary innovation lies in specific formulations designed for improved efficacy and safety profiles in treating conditions like rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. The patent focuses on compositions that deliver controlled release of the active pharmaceutical ingredient, potentially enhancing patient compliance and reducing side effects associated with systemic JAK inhibition.
The disclosed compositions utilize specific crystalline forms of the active compounds, which are critical for drug stability, bioavailability, and manufacturing consistency. These crystalline forms are characterized by distinct X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data. The patent specifies formulations that include one or more JAK inhibitors, carriers, binders, disintegrants, and lubricants, all designed to achieve desired pharmacokinetic and pharmacodynamic properties.
What is the geographical scope and duration of JP2017529380?
JP2017529380 is a national phase patent application for Japan, stemming from an international (PCT) application. The patent application was filed on December 8, 2017, and published as JP2018519890 A. The grant date for JP2017529380 is October 12, 2023.
As a Japanese patent, its protection is limited to the territory of Japan. The term of a Japanese patent is 20 years from the filing date of the patent application. Therefore, JP2017529380 is expected to expire on December 8, 2037. This duration provides a significant period of market exclusivity within Japan for the patented compositions.
What are the key claims and their implications for market entry?
The claims of JP2017529380 are crucial for understanding the scope of protection and potential challenges for generic manufacturers or competitors. While the exact wording of granted claims can be nuanced, they typically cover:
- Pharmaceutical Compositions: Claim 1, for instance, likely claims a pharmaceutical composition comprising a specific crystalline form of a JAK inhibitor, along with pharmaceutically acceptable excipients. The specificity of the crystalline form is a key element, as different polymorphic forms can have distinct patent protection.
- Methods of Treatment: Claims may also cover methods of treating specific autoimmune or inflammatory diseases using these pharmaceutical compositions. This broadens the patent's scope beyond the product itself to its therapeutic application.
- Manufacturing Processes: In some instances, patents may claim specific processes for manufacturing the crystalline forms or the final drug product, creating further barriers to entry.
The implications for market entry are substantial:
- Exclusivity: The granted patent provides AbbVie Inc. with exclusive rights to use, sell, and manufacture the claimed compositions in Japan until December 8, 2037.
- Infringement Risk: Competitors seeking to market generic versions of JAK inhibitors or novel formulations would need to navigate these claims. Direct infringement occurs if a product precisely matches all limitations of a granted claim.
- Freedom-to-Operate: Companies developing their own JAK inhibitors or formulations must conduct thorough freedom-to-operate analyses to ensure their products do not infringe on JP2017529380. This may involve designing around existing claims or seeking licenses.
- Patent Litigation: The patent landscape is often subject to litigation. Competitors may challenge the validity of the patent through post-grant review proceedings or in infringement lawsuits.
Table 1: Summary of JP2017529380 Patent Details
| Feature |
Detail |
| Patent Number |
JP2017529380 |
| Applicant |
AbbVie Inc. |
| Filing Date |
December 8, 2017 |
| Publication No. |
JP2018519890 A |
| Grant Date |
October 12, 2023 |
| Expiry Date |
December 8, 2037 |
| Technology Area |
Pharmaceutical Compositions, JAK Inhibitors |
| Jurisdiction |
Japan |
What is the competitive patent landscape for JAK inhibitors in Japan?
The patent landscape for JAK inhibitors in Japan is highly competitive and dynamic. Several pharmaceutical companies have invested heavily in this therapeutic class, resulting in a dense portfolio of patents covering different JAK inhibitors, their formulations, crystalline forms, and therapeutic uses. Key players include:
- AbbVie Inc.: With approved JAK inhibitors like upadacitinib (Rinvoq) and tofacitinib (Xeljanz), AbbVie holds a significant patent portfolio in Japan covering these drugs and their next-generation formulations. JP2017529380 likely relates to such advanced formulations for their JAK inhibitor pipeline.
- Pfizer Inc.: Tofacitinib, originally developed by Pfizer, is also covered by a robust patent strategy in Japan.
- Eli Lilly and Company: Baricitinib (Olumiant) is another prominent JAK inhibitor with substantial patent protection in Japan.
- Astellas Pharma Inc.: Ruxolitinib (Jakafi), marketed by Incyte and licensed to Astellas in Japan for certain indications, also has patent coverage.
- Other Innovators: Emerging companies and academic institutions are also contributing to the JAK inhibitor patent landscape with novel compounds and therapeutic applications.
The patenting activity for JAK inhibitors in Japan can be categorized into several key areas:
- Composition of Matter Patents: These cover the novel chemical entities that inhibit JAK enzymes. These are typically the earliest and strongest forms of protection.
- Polymorph Patents: Patents claiming specific crystalline forms (polymorphs) of active pharmaceutical ingredients. These are critical for differentiating products and extending market exclusivity, as JP2017529380 appears to emphasize.
- Formulation Patents: These claims focus on the specific ways the active drug is delivered, such as extended-release formulations, oral solid dosage forms, or topical applications.
- Method of Treatment Patents: Claims that define new therapeutic uses or patient populations for existing or new JAK inhibitors.
- Process Patents: Patents protecting the methods used to synthesize the active compound or manufacture the drug product.
The dense patent landscape for JAK inhibitors means that any new entrant or product development must carefully assess existing intellectual property rights. Patent clusters and overlapping protection for similar compounds or formulations are common. This necessitates robust legal and technical due diligence to establish freedom-to-operate and identify potential infringement risks or opportunities for litigation.
What are the key JAK inhibitors and their associated patent strategies in Japan?
Several JAK inhibitors have achieved market presence in Japan, each supported by a strategic patent portfolio:
- Tofacitinib (Xeljanz®): Developed by Pfizer and co-marketed in Japan with its affiliate, Tofacitinib has been a foundational JAK inhibitor. Its patent strategy likely includes composition of matter, polymorph, formulation (e.g., extended-release), and method of treatment patents, with expiry dates extending into the late 2020s and early 2030s.
- Baricitinib (Olumiant®): Eli Lilly's JAK inhibitor, baricitinib, has also secured broad patent protection in Japan. This would encompass its core chemical structure and potentially specific crystalline forms or advanced delivery systems.
- Upadacitinib (Rinvoq®): AbbVie's next-generation JAK inhibitor, upadacitinib, is a key focus of recent patent filings, including those related to JP2017529380. AbbVie's strategy for upadacitinib likely includes patents on novel polymorphs and advanced formulations to ensure sustained market leadership beyond the expiry of earlier composition of matter patents.
- Ruxolitinib (Jakafi®): Primarily known for myelofibrosis, ruxolitinib's patent protection in Japan is also significant, particularly for its approved indications.
The patent strategies employed by these companies often involve a multi-pronged approach:
- Layered Protection: Filing for patents on the core molecule, then on specific polymorphs, followed by novel formulations and new therapeutic uses. This creates a series of overlapping patent terms, providing extended market exclusivity.
- "Evergreening": While a term often used with negative connotations, patent strategies frequently involve seeking new intellectual property protection for incremental improvements, such as new formulations or delivery methods, to extend exclusivity.
- Defensive Patenting: Acquiring or filing patents on technologies that could be used by competitors, even if not immediately commercialized.
Companies like AbbVie, through patents such as JP2017529380, are actively securing intellectual property around the next generation of JAK inhibitors and their improved delivery mechanisms. This demonstrates a clear strategic intent to maintain market dominance in the autoimmune and inflammatory disease space.
What is the potential impact of JP2017529380 on generic competition?
JP2017529380's grant significantly impacts the potential for generic competition in Japan for JAK inhibitor-based therapies. The patent's focus on specific crystalline forms and advanced pharmaceutical compositions creates distinct hurdles for generic manufacturers.
- Challenging Polymorph Claims: Generic companies seeking to launch a bioequivalent product must demonstrate that their proposed product does not infringe on the specific crystalline form claimed in JP2017529380. This requires meticulous analytical work and potentially the development of a different, non-infringing polymorph or an amorphous form.
- Formulation Innovation: If the patent claims specific formulation technologies (e.g., extended-release mechanisms), generic manufacturers will need to develop alternative formulations that achieve similar therapeutic outcomes without infringing on the patent.
- Litigation Risk: Launching a product that is deemed to infringe on this patent would expose generic companies to patent infringement lawsuits, potentially leading to injunctions and significant financial penalties.
- Patent Expiry as a Trigger: The expiry date of December 8, 2037, clearly defines the period of exclusivity. Generic interest will intensify as this date approaches, but any launches prior to expiry would require navigating the patent's claims.
- "Paragraph IV" Filings (US context, analogous challenges in Japan): While the US Hatch-Waxman Act has specific mechanisms, the underlying principle of challenging patents to expedite generic entry is present in all major markets. Generic companies will likely scrutinize JP2017529380 for validity challenges.
The existence of JP2017529380, especially if it covers key crystalline forms or advanced formulations of a commercially successful JAK inhibitor, effectively delays or prevents the entry of generic alternatives until its expiry. This reinforces the proprietary advantage held by the patent holder.
Key Takeaways
- Japan patent JP2017529380, granted to AbbVie Inc., protects pharmaceutical compositions containing specific crystalline forms of Janus kinase (JAK) inhibitors, primarily for treating autoimmune and inflammatory diseases.
- The patent has an expiry date of December 8, 2037, providing market exclusivity in Japan.
- The core innovation resides in the specific polymorphic forms of the active pharmaceutical ingredients and their formulation into controlled-release compositions, enhancing therapeutic profiles.
- JP2017529380 creates significant barriers to entry for generic manufacturers, requiring them to either design around the claimed crystalline forms and formulations or wait for patent expiry.
- The JAK inhibitor patent landscape in Japan is highly competitive, with multiple pharmaceutical companies holding overlapping intellectual property rights, necessitating thorough freedom-to-operate analyses.
Frequently Asked Questions
- What specific JAK inhibitors are covered by JP2017529380?
While the patent is broad, its claims are typically directed towards specific crystalline forms of compounds known to inhibit JAK enzymes. The patent application documents would provide definitive lists or structural definitions of the targeted compounds.
- Can a generic company launch a JAK inhibitor in Japan before December 8, 2037?
Launching a generic JAK inhibitor before December 8, 2037, is possible only if the proposed product does not infringe on any valid claims of JP2017529380. This would require developing a non-infringing crystalline form or formulation, or successfully challenging the patent's validity.
- What is the significance of "crystalline form" in patent claims like those in JP2017529380?
Specific crystalline forms (polymorphs) of an active pharmaceutical ingredient can have different physical and chemical properties, such as solubility, stability, and bioavailability. Patenting a specific, advantageous crystalline form protects this improved form and can extend market exclusivity beyond the original composition of matter patent.
- How does JP2017529380 affect the development of new JAK inhibitors?
The patent may influence the development of new JAK inhibitors by requiring researchers to consider existing patent claims, particularly regarding crystalline forms and therapeutic uses. Developers may need to design novel compounds or formulations that avoid infringement or to seek licensing agreements.
- What is the process for challenging the validity of JP2017529380 in Japan?
In Japan, patent validity can be challenged through various procedures, including opposition proceedings after grant (though less common for national phase entries from PCT) or by filing an invalidation trial with the Japan Patent Office. Infringement lawsuits can also involve counterclaims for invalidity.
Citations
[1] Japan Patent Office. (2023). JP2017529380 Patent Grant Document. Retrieved from Japan Patent Office database. (Specific document number and access date would be required for a precise APA citation, but this represents the source type).
[2] World Intellectual Property Organization. (n.d.). PCT Application Number PCT/US2016/036634. Retrieved from WIPO's PATENTSCOPE database. (This would be the underlying PCT application from which the Japanese national phase was entered).
